- Home
- EYPT
as 12-18-2024 10:36am EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 594.5M | IPO Year: | 2005 |
| Target Price: | $27.29 | AVG Volume (30 days): | 918.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.21 - $30.99 | Next Earning Date: | 11-07-2024 |
| Revenue: | $45,713,000 | Revenue Growth: | 7.50% |
| Revenue Growth (this year): | -5.25% | Revenue Growth (next year): | -63.95% |
Latest EyePoint Pharmaceuticals Inc. News
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
TipRanks
a day ago
EyePoint reports inducement grants under NASDAQ listing rule
GlobeNewswire
a day ago
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2 days ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TipRanks
13 days ago
EyePoint doses first patient in second Phase 3 LUCIA clinical trial
GlobeNewswire
14 days ago
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
GlobeNewswire
a month ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Zacks
a month ago
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
TipRanks
a month ago
EyePoint price target lowered to $33 from $38 at Baird
Compare EYPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.